[Glimepiride].
Nakamura
Naoto
N
First Department of Internal Medicine, Kyoto Prefectural University of Medicine.
D018528:ATP-Binding Cassette Transporters; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D005905:Glyburide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D007333:Insulin Resistance; D015221:Potassium Channels / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D064233:Sulfonylurea Receptors
D018528:ATP-Binding Cassette Transporters; D007004:Hypoglycemic Agents; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; D011955:Receptors, Drug; D013453:Sulfonylurea Compounds; D064233:Sulfonylurea Receptors; C057619:glimepiride; D000255:Adenosine Triphosphate; D005905:Glyburide